Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients.
Epstein-Barr virus (EBV) infection is recognized as the principal aetiological factor in the pathogenesis of post-transplant lymphoproliferative disease (PTLD), particularly when primary EBV infection occurs after transplantation. We analysed, using a time-dependent proportional hazards model, the factors associated with development of PTLD in 40 adult liver transplant recipients who were seronegative for EBV prior to transplantation. Of 40 patients, 13 (33%) had a tissue diagnosis of PTLD at a median time of 126 days after transplantation. The multivariate analysis showed that prior CMV disease, the number of steroid boluses given and the number of units of RBC and FFP transfused were significant risk factors for development of PTLD.
Mañez
R
R
Department of Surgery and Infectious Diseases and Microbiology, School of Medicine and Graduate School of Public Health, University of Pittsburgh, Pennsylvania, USA.
Breinig
M K
MK
Linden
P
P
Kusne
S
S
Torre-Cisneros
J
J
Wilson
J
J
Starzl
T E
TE
Ho
M
M
D000328:Adult; D016913:Blood Component Transfusion; D003586:Cytomegalovirus Infections / Q000150:complications; D004359:Drug Therapy, Combination; D017707:Erythrocyte Transfusion; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D015999:Multivariate Analysis; D011183:Postoperative Complications; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D007166:Immunosuppressive Agents